A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Novartis
Institut Paoli-Calmettes
University of Oklahoma
University of California, Davis
Jemincare
Kyowa Kirin Co., Ltd.
Merck Sharp & Dohme LLC
SRH Wald-Klinikum Gera GmbH
Maastricht University Medical Center
Charite University, Berlin, Germany
LEO Pharma
LEO Pharma
Almirall, S.A.
Hull University Teaching Hospitals NHS Trust
Zealand University Hospital
Erasmus Medical Center
Psoriasis Treatment Center of Central New Jersey
RECORDATI GROUP
Royal Cornwall Hospitals Trust
University of California, Irvine
Medical University of Graz
Erasmus Medical Center
Clinigen, Inc.
Medical University of Graz
Wake Forest University Health Sciences
Assistance Publique Hopitaux De Marseille
Oslo University Hospital
Pierre Fabre Medicament
University Hospital, Bordeaux
University Medical Center Groningen
Peter MacCallum Cancer Centre, Australia
University Hospitals Cleveland Medical Center
Goldman, Butterwick, Fitzpatrick and Groff
University of California, San Francisco
Viatris Inc.
Viatris Inc.
Polish Lymphoma Research Group
Medical University of Graz
Novartis
Galderma R&D
Clinigen, Inc.
University Hospital Regensburg
Fundacion Clinic per a la Recerca Biomédica
Mayo Clinic
Hoffmann-La Roche
Bausch Health Americas, Inc.
University of Campania Luigi Vanvitelli
Goldman, Butterwick, Fitzpatrick and Groff